Hirofumi Utsumi

5.2k total citations
27 papers, 619 citations indexed

About

Hirofumi Utsumi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Hirofumi Utsumi has authored 27 papers receiving a total of 619 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 6 papers in Physiology. Recurrent topics in Hirofumi Utsumi's work include Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Asthma and respiratory diseases (5 papers). Hirofumi Utsumi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Asthma and respiratory diseases (5 papers). Hirofumi Utsumi collaborates with scholars based in Japan, United States and United Kingdom. Hirofumi Utsumi's co-authors include Kazuyoshi Kuwano, Hiroshi Wakui, Hiroshi Nokihara, Noboru Yamamoto, Yutaka Fujiwara, Yusuke Okuma, Sadamu Homma, Satoru Kitazono, Yukiko Sagawa and Yukio Hosomi and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Annals of Oncology.

In The Last Decade

Hirofumi Utsumi

24 papers receiving 615 citations

Peers

Hirofumi Utsumi
Eo-Jin Kim South Korea
A. Spada Italy
Esmée P. Hoefsmit Netherlands
Harunori Nakashima Japan
Gustavo Schvartsman Brazil
Lauren Xu United States
Sarah Morgan United States
Mónica García‐Cosío Spain
Ryuzo Kanno Japan
Camille Schiffler France
Eo-Jin Kim South Korea
Hirofumi Utsumi
Citations per year, relative to Hirofumi Utsumi Hirofumi Utsumi (= 1×) peers Eo-Jin Kim

Countries citing papers authored by Hirofumi Utsumi

Since Specialization
Citations

This map shows the geographic impact of Hirofumi Utsumi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hirofumi Utsumi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hirofumi Utsumi more than expected).

Fields of papers citing papers by Hirofumi Utsumi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hirofumi Utsumi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hirofumi Utsumi. The network helps show where Hirofumi Utsumi may publish in the future.

Co-authorship network of co-authors of Hirofumi Utsumi

This figure shows the co-authorship network connecting the top 25 collaborators of Hirofumi Utsumi. A scholar is included among the top collaborators of Hirofumi Utsumi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hirofumi Utsumi. Hirofumi Utsumi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Fujita, Yu, Shota Fujimoto, Atsushi Miyamoto, et al.. (2023). Fibroblast-derived Extracellular Vesicles Induce Lung Cancer Progression in the Idiopathic Pulmonary Fibrosis Microenvironment. American Journal of Respiratory Cell and Molecular Biology. 69(1). 34–44. 9 indexed citations
4.
Nakazawa, Yusuke, et al.. (2022). Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World Journal of Clinical Oncology. 13(7). 641–651. 4 indexed citations
5.
Hara, Hiromichi, Jun Araya, Hirofumi Utsumi, et al.. (2021). Possible relationship between esophageal dilatation and severity of M. abscessus pulmonary disease. PLoS ONE. 16(12). e0261866–e0261866. 2 indexed citations
6.
Numata, Takanori, Jun Araya, Yu Fujita, et al.. (2021). Effectiveness of Switching Biologics for Severe Asthma Patients in Japan: A Single-Center Retrospective Study. Journal of Asthma and Allergy. Volume 14. 609–618. 26 indexed citations
7.
Numata, Takanori, Hironori Kawamoto, Masahiro Yoshida, et al.. (2020). Predictors of the enhanced response to mepolizumab treatment for severe eosinophilic asthma: A retrospective, long-term study. SHILAP Revista de lepidopterología. 7(1). 8 indexed citations
8.
Numata, Takanori, Hirofumi Utsumi, Mitsuo Hashimoto, et al.. (2020). Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study. BMC Pulmonary Medicine. 20(1). 207–207. 26 indexed citations
9.
Utsumi, Hirofumi, Jun Araya, Junko Watanabe, et al.. (2020). Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report. Cancer Immunology Immunotherapy. 69(10). 2033–2039. 15 indexed citations
10.
Hasegawa, Tsukasa, Noriko Yanagitani, Hirofumi Utsumi, et al.. (2019). Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer. Anticancer Research. 39(12). 6851–6857. 27 indexed citations
11.
Numata, Takanori, Katsutoshi Nakayama, Hirofumi Utsumi, et al.. (2019). Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. BMC Pulmonary Medicine. 19(1). 176–176. 34 indexed citations
12.
Numata, Takanori, Katsutoshi Nakayama, Satoko Fujii, et al.. (2018). Risk factors of postoperative pulmonary complications in patients with asthma and COPD. BMC Pulmonary Medicine. 18(1). 4–4. 35 indexed citations
13.
Okuma, Yusuke, Hiroshi Wakui, Hirofumi Utsumi, et al.. (2018). Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer. Clinical Lung Cancer. 19(5). 410–417.e1. 115 indexed citations
14.
Hara, Hiromichi, Hirofumi Utsumi, Hiroshi Wakui, et al.. (2017). Drug reaction or metastatic lung cancer?. Cleveland Clinic Journal of Medicine. 84(12). 914–915.
15.
Hashimoto, Mitsuo, Ayako Kojima, Ryoko Sasaki, et al.. (2017). Mild Lung Tuberculosis in a Patient Suffering from Status Epilepticus Caused by the Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH). Internal Medicine. 56(4). 429–433. 1 indexed citations
16.
Kanda, Shintaro, Hideaki Shiraishi, Ayako Tanaka, et al.. (2016). Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Annals of Oncology. 27(12). 2242–2250. 85 indexed citations
17.
Numata, Takanori, Katsutoshi Nakayama, Nayuta Saito, et al.. (2016). Risk factors of postoperative pulmonary complications in bronchial asthma and COPD patients. PA5019–PA5019.
18.
Kitazono, Satoru, Yutaka Fujiwara, Koji Tsuta, et al.. (2015). Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 16(5). 385–390. 109 indexed citations
19.
Katsuya, Yuki, Yutaka Fujiwara, Kuniko Sunami, et al.. (2015). Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer. Cancer Chemotherapy and Pharmacology. 76(1). 125–132. 13 indexed citations
20.
Fujiwara, Yutaka, Hiroshi Nokihara, Yasuhide Yamada, et al.. (2015). Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 76(6). 1143–1152. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eo-Jin Kim Breakdown of academic impact, for papers by A. Spada Breakdown of academic impact, for papers by Esmée P. Hoefsmit Breakdown of academic impact, for papers by Harunori Nakashima Breakdown of academic impact, for papers by Gustavo Schvartsman Breakdown of academic impact, for papers by Lauren Xu Breakdown of academic impact, for papers by Sarah Morgan Breakdown of academic impact, for papers by Mónica García‐Cosío Breakdown of academic impact, for papers by Ryuzo Kanno Breakdown of academic impact, for papers by Camille Schiffler
Rankless by CCL
2026